JP2002518347A5 - - Google Patents

Download PDF

Info

Publication number
JP2002518347A5
JP2002518347A5 JP2000554401A JP2000554401A JP2002518347A5 JP 2002518347 A5 JP2002518347 A5 JP 2002518347A5 JP 2000554401 A JP2000554401 A JP 2000554401A JP 2000554401 A JP2000554401 A JP 2000554401A JP 2002518347 A5 JP2002518347 A5 JP 2002518347A5
Authority
JP
Japan
Prior art keywords
shows
antibodies
val
psa
prt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000554401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002518347A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB1999/001115 external-priority patent/WO1999065523A1/en
Publication of JP2002518347A publication Critical patent/JP2002518347A/ja
Publication of JP2002518347A5 publication Critical patent/JP2002518347A5/ja
Pending legal-status Critical Current

Links

JP2000554401A 1998-06-15 1999-06-15 前立腺癌治療のための免疫療法組成物および方法 Pending JP2002518347A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8928198P 1998-06-15 1998-06-15
US60/089,281 1998-06-15
PCT/IB1999/001115 WO1999065523A1 (en) 1998-06-15 1999-06-15 Immunotherapeutic composition and method for the treatment of prostate cancer

Publications (2)

Publication Number Publication Date
JP2002518347A JP2002518347A (ja) 2002-06-25
JP2002518347A5 true JP2002518347A5 (cg-RX-API-DMAC7.html) 2007-01-18

Family

ID=22216751

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000554401A Pending JP2002518347A (ja) 1998-06-15 1999-06-15 前立腺癌治療のための免疫療法組成物および方法

Country Status (9)

Country Link
US (3) US6881405B2 (cg-RX-API-DMAC7.html)
EP (1) EP1085905B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002518347A (cg-RX-API-DMAC7.html)
AT (1) ATE480566T1 (cg-RX-API-DMAC7.html)
AU (1) AU768002B2 (cg-RX-API-DMAC7.html)
CA (1) CA2328504A1 (cg-RX-API-DMAC7.html)
DE (1) DE69942742D1 (cg-RX-API-DMAC7.html)
IL (1) IL139700A (cg-RX-API-DMAC7.html)
WO (1) WO1999065523A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
ATE480566T1 (de) * 1998-06-15 2010-09-15 Quest Pharmatech Inc Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
MXPA01007148A (es) 1999-01-13 2002-03-27 Igeneon Krebs Immuntherapie Uso de anticuerpos para vacunacion anti-cancer.
CA2408547A1 (en) * 2000-05-11 2001-11-15 Altarex Corp. Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
HRP20041037A2 (en) * 2002-04-11 2005-06-30 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
EP1578445A4 (en) * 2002-10-17 2007-04-04 Altarex Medical Corp THERAPEUTIC ADJUVANS
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US20080095790A1 (en) * 2006-10-24 2008-04-24 Perambakam Supriya M Methods of Treating Prostate Cancer
ES2588705T3 (es) * 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
EP2331130B1 (en) * 2008-04-09 2018-02-14 Oncoquest Inc. Ige antibodies for the treatment of cancer
CA2723918C (en) 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
GB0811567D0 (en) * 2008-06-24 2008-07-30 Cytosystems Ltd Assay
PL3912643T3 (pl) 2009-02-13 2023-01-23 Immunomedics Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
WO2011034660A1 (en) 2009-09-16 2011-03-24 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
IN2012DN03354A (cg-RX-API-DMAC7.html) 2009-12-02 2015-10-23 Immunomedics Inc
US9023802B2 (en) * 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
IN2014CN02581A (cg-RX-API-DMAC7.html) 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
ES2978993T3 (es) 2014-02-21 2024-09-23 Ibc Pharmaceuticals Inc Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
PL3204018T3 (pl) 2014-10-07 2022-01-03 Immunomedics, Inc. Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
EP3286224A4 (en) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
EP4342497A1 (en) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antibody having reduced binding affinity for antigen

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865689A (en) 1972-11-09 1975-02-11 Hoffmann La Roche Method of producing carcinoembryonic antigens
US4446122A (en) 1979-12-28 1984-05-01 Research Corporation Purified human prostate antigen
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5053224A (en) 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
DE3650139T2 (de) 1985-07-05 1995-03-09 Hutchinson Fred Cancer Res Verfahren zum reduzieren der immunogenizität und zum induzieren immunologischer toleranz.
EP0234122A3 (en) 1986-02-21 1989-03-22 Oncogen Limited Partnership Tumor therapy with biologically active anti-tumor antibodies
AU613590B2 (en) 1986-11-19 1991-08-08 Bristol-Myers Squibb Company Hybridomas producing monoclonal antibodies to new mucin epitopes
US5059680A (en) 1986-11-24 1991-10-22 Centocor, Inc. Method of isolating ca 125 antigen
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
GB8728856D0 (en) 1987-12-10 1988-01-27 Bradwell A R Tumour-locating agents & method of locating tumours
CA2065874C (en) 1989-09-15 2001-12-11 Joseph P. Brown Hybridoma ct43 producing a monoclonal antibody to a mucin epitope of colorectal cancer
US5165922A (en) 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
DE4133791A1 (de) 1991-10-11 1993-04-15 Behringwerke Ag Monoklonale antikoerper gegen tumorassoziierte antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0652014A1 (en) * 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
US5773292A (en) 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US6143509A (en) 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
GB9606228D0 (en) 1996-03-25 1996-05-29 Secr Defence Apparatus for matrix coating fibres with metal vapour
AU4086397A (en) 1996-09-06 1998-03-26 Centocor Inc. Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen
ATE480566T1 (de) * 1998-06-15 2010-09-15 Quest Pharmatech Inc Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs

Similar Documents

Publication Publication Date Title
US5869620A (en) Multivalent antigen-binding proteins
HUP0303173A2 (hu) Csökkent immunogenitású, módosított anti-EGFR-ellenanyagok
CA2410604A1 (en) Use of coiled-coil structural scaffold to generate structure-specific peptides
UA87093C2 (ru) ГУМАНИЗИРОВАННЫЙ ИММУНОГЛОБУЛИН, КОТОРЫЙ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С БЕТА-АМИЛОИДНЫМ ПЕПТИДОМ (Аβ)
Vichier‐Guerre et al. Induction of carbohydrate‐specific antibodies in HLA‐DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use
CA2249746A1 (en) Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
Losman et al. Baboon anti‐idiotype antibodies mimic a carcinoembryonic antigen epitope
RU2001130068A (ru) Антиидиотипические антитела к антителам, которые ингибируют связывание иммуноглобулина с его высокоаффинным рецептором
JP2003514028A (ja) ワクチンとしての抗体の新たな使用
Reinartz et al. Immunological properties of a single-chain fragment of the anti-idiotypic antibody ACA125
Losman et al. Mimicry of a carcinoembryonic antigen epitope by a rat monoclonal anti‐idiotype antibody
JP2007161700A (ja) メラノーマに対する免疫応答を刺激するためのペプチド
EP0957111B1 (en) Specific binding proteins for treating canine allergy
de Moraes et al. Induction of an immune response through the idiotypic network with monoclonal anti‐idiotype antibodies in the carcinoembryonic antigen system
Lehmann et al. Tumor‐antigen‐specific humoral immune response of animals to anti‐idiotypic antibodies and comparative serological analysis of patients with small‐cell lung carcinoma
Rhodin et al. Characterization of the Streptococcus mutans P1 epitope recognized by immunomodulatory monoclonal antibody 6-11A
Senpuku et al. Identification of a repeated epitope recognized by human serum antibodies in a surface protein antigen of Streptococcus mutans
PL175651B1 (pl) Antyidiotypowe mysie przeciwciała monoklonalne oraz sposób wytwarzania antyidiotypowych przeciwciał monoklonalnych
AU757334B2 (en) Specific binding proteins for treating canine allergy
Bufe Significance of IgE-binding epitopes in allergic disease
WO2001036485A3 (es) Anticuerpo monocolonal recombinante que reconoce el antigeno ior c2 su uso para el diagnostico y tratamiento de tumores colorectales
Ma et al. Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response
Rio et al. Idiotypic restriction of murine monoclonal antibodies to a defined antigenic region of human thyroglobulin
Muller Immunization with peptides
EP0955311A2 (en) Peptide vaccine for canine allergy